Peptide Hormones and the Endocrine Axis: GH, GHRH, Ghrelin, and Feedback Loops

Research Disclaimer: All compounds described are sold exclusively for in-vitro and laboratory research use. Not for unsupervised use. This content does not constitute medical advice.

Growth hormone (GH) secretion is regulated by a multilevel neuroendocrine axis with multiple stimulatory and inhibitory signals. This complexity — far greater than simple "GH is secreted from pituitary" — is why different research peptides produce different GH secretion profiles. Understanding the axis architecture is foundational for interpreting GH secretagogue research data and designing valid GH axis protocols.

The GH/IGF-1 Axis: Full Architecture#

Level 1 — Hypothalamus:

• GHRH neurons (arcuate nucleus): release GHRH (Growth Hormone-Releasing Hormone, 44 AA)

  • GHRH → GHRHR on somatotrophs → Gαs → cAMP → PKA → GH gene expression + GH secretion
  • Released episodically → drives GH pulse generation

• Somatostatin neurons (periventricular nucleus): release SRIF/somatostatin

  • SRIF → SSTR2/SSTR5 on somatotrophs → Gαi → ↓ cAMP → inhibits GH release
  • Released cyclically: alternates with GHRH pulses; creates the pulsatile pattern

• Ghrelin-responsive neurons: hypothalamic ghrelin → kisspeptin → GnRH interaction

  • Ghrelin also acts directly at hypothalamic GHSR-1a → amplifies GHRH effect

Level 2 — Pituitary (Anterior):

• Somatotrophs (GH-producing cells): ~50% of anterior pituitary
• Respond to GHRH (stimulatory) and SRIF (inhibitory) → release GH in pulses
• GH release characteristics: 5–7 pulses/day (humans); larger, fewer pulses in males vs. females
• Peak nocturnal GH pulse in humans: corresponds to slow-wave sleep

Level 3 — Liver:

• GH → GH receptor (JAK2/STAT5) on hepatocytes → IGF-1 synthesis
• IGF-1 released into circulation → ~80% bound to IGFBP-3 (carrier protein)
• Serum IGF-1 level reflects integrated GH secretion over ~24h (stable marker)

Level 4 — Negative Feedback:

• GH → hypothalamus: stimulates somatostatin → inhibits next GH pulse
• IGF-1 → hypothalamus: stimulates somatostatin; reduces GHRH
• IGF-1 → pituitary: directly inhibits GH secretion (at somatotrophs)
• Result: self-limiting GH secretion — each pulse triggers feedback that suppresses the next

Ghrelin and GHSR-1a: The Third Axis#

Ghrelin (28 AA, acylated at Ser3):

• Produced primarily in gastric A-like cells
• Fasting → increased ghrelin → appetite stimulation + GH secretion
• Ghrelin → GHSR-1a (same receptor as research GH secretagogues)
• GHSR-1a activation → Gαq → PKC → IP3 → Ca2+ → GH secretion
• Mechanistic note: ghrelin acts at both hypothalamus (amplifies GHRH) AND directly at pituitary (direct GH release)

How synthetic GH secretagogues (Ipamorelin, GHRP-6) work: They mimic ghrelin's pharmacophore at GHSR-1a → produce GH pulse by:

1. Direct pituitary effect: GHSR-1a on somatotrophs → direct GH release
2. Hypothalamic effect: GHSR-1a on hypothalamic neurons → GHRH release (indirect amplification)

The synergy with GHRH analogs: CJC-1295 acts on GHRHR (separate receptor from GHSR-1a). When ipamorelin + CJC-1295 are combined:

• Two separate receptors activated simultaneously on somatotrophs
• GHRHR (Gαs → cAMP) + GHSR-1a (Gαq → PKC) → supra-additive GH release
• Published data: combination produces 2–4× greater GH peak than either alone

GH Pulse Physiology: Why Pulsatility Matters#

Continuous vs. pulsatile GH:

• Continuous GH infusion → paradoxically leads to GHR downregulation → reduced IGF-1 → tachyphylaxis
• Pulsatile GH → GHR remains responsive → full IGF-1 production
• This is why physiological GH pulsatility produces stronger anabolic effects than continuous synthetic GH at the same dose

Sex differences in GH pulse:

• Males: high-amplitude, low-frequency pulses (peak at night)
• Females: lower amplitude but more frequent pulses → different hepatic IGF-1 response
• Rodents: similar sex dimorphism in pulse pattern

Research relevance:

• MK-677 (oral GHS): continuous GHSR-1a stimulation → reduces pulsatility → slightly attenuated GH response over time vs. twice-daily injection of ipamorelin
• Ipamorelin twice daily: restores pulsatility at each injection → receptor recycling between doses → maintained responsiveness

Somatopause: Age-Related GH Axis Decline#

What happens with aging:

1. GHRH pulse amplitude declines (hypothalamic GHRH neuron loss)
2. Somatostatin tone increases (less suppression of inhibitory tone → blunted GH peaks)
3. Ghrelin sensitivity may decrease
4. Net: GH pulse amplitude ~50% lower at 60 vs. 20 years; IGF-1 declines proportionally

Research intervention points:

• GHRH analog (CJC-1295): restores GHRHR stimulation despite reduced hypothalamic input
• GHSR-1a agonist (ipamorelin, MK-677): bypasses hypothalamic GHRH deficiency → stimulates somatotrophs directly
• Published data: MK-677 in older adults significantly elevated IGF-1 levels (7-day supplementation → 55% IGF-1 increase in phase II study)

Measuring GH Axis Activity in Research#

Serum GH:

• Pulsatile: single time-point is unreliable
• Gold standard: frequent sampling (every 10–20 min × 6h) for area-under-curve (AUC) measurement
• Stimulation tests: clonidine, ITT, or GH secretagogue challenge test for pituitary reserve

Serum IGF-1:

• Stable over 24h (bound to IGFBP-3)
• Reflects integrated GH secretion → best single biomarker for chronic GH axis activity
• Normal reference ranges age-dependent (publish alongside absolute values)

IGFBP-3:

• Primary IGF-1 carrier; GH-regulated
• Rises and falls in proportion to IGF-1
• Combined IGF-1 + IGFBP-3 gives fuller picture of GH axis activity

Research Use Only. JuicedPharma does not provide medical advice.

Published by JuicedPharma Research Team · October 2026 · Category: Growth Hormone